By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating in Copenhagen, Denmark, by NewsRx journalists, research stated, "Breast cancer is a very heterogeneous disease, encompassing several intrinsic subtypes with various morphological and molecular features, natural history and response to therapy. Currently, molecular targeted therapies are available for estrogen receptor (ER)(-) and human epidermal growth factor receptor 2 (Her2)-positive breast tumors."
The news reporters obtained a quote from the research from the Institute of Cancer Biology, "However, a significant proportion of primary breast cancers are negative for ER, progesterone receptor (PgR), and Her2, comprising the triple negative breast cancer (TNBC) group. Women with TNBC have a poor prognosis because of the aggressive nature of these tumors and current lack of suitable targeted therapies. As a consequence, the identification of novel relevant protein targets for this group of patients is of great importance. Using a systematic two dimensional (2D) gel-based proteomic profiling strategy, applied to the analysis of fresh TNBC tissue biopsies, in combination with a three-tier orthogonal technology (two dimensional PAGE/silver staining coupled with MS, two dimensional Western blotting, and immunohistochemistry) approach, we aimed to identify targetable protein markers that were present in a significant fraction of samples and that could define therapy-amenable sub-groups of TNBCs. We present here our results, including a large cumulative database of proteins based on the analysis of 78 TNBCs, and the identification and validation of one specific protein, Mage-A4, which was expressed in a significant fraction of TNBC and Her2-positive/ER negative lesions. The high level expression of Mage-A4 in the tumors studied allowed the detection of the protein in the tumor interstitial fluids as well as in sera."
According to the news reporters, the research concluded: "The existence of immunotherapeutics approaches specifically targeting this protein, or Mage-A protein family members, and the fact that we were able to detect its presence in serum suggest novel management options for TNBC and human epidermal growth factor receptor 2 positive/estrogen receptor negative patients bearing Mage-A4 positive tumors."
For more information on this research see: Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Molecular and Cellular Proteomics, 2013;12(2):381-94. (American Society for Biochemistry and Molecular Biology - www.asbmb.org; Molecular and Cellular Proteomics - www.mcponline.org/)
Our news correspondents report that additional information may be obtained by contacting T. Cabezon, Dept. of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, DK-2100, Copenhagen, Denmark. Additional authors for this research include I. Gromova, P. Gromov, R. Serizawa, V. Timmermans Wielenga, N. Kroman, J.E. Celis and J.M Moreira (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Europe, Tumors, Denmark, Hormones, Oncology, Carcinoma, Copenhagen, Proteomics, Therapeutics, Breast Cancer, Endocrinology, Women's Health, Steroid Receptors, Estrogen Receptors, Cancer Gene Therapy, DNA Binding Proteins, Transcription Factors.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC